Epic Bio Presents First Data Supporting Persistent and Tunable Gene Activation Using Transient Delivery

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, presented multiple datasets demonstrating persistent gene activation at the 6th International Conference on Epigenetics and Bioengineering, on October 29, 2022, in Houston, Texas. “This conference was a pivotal moment for...

Click to view original post